BACKGROUND Bioprosthetic aortic valve degeneration is increasingly common, often unheralded, and can have
T he implantation of bioprosthetic heart valves is increasing rapidly due to patient preference, the increasing prevalence of valve disease in an aging population, and the emergence of transcatheter aortic valve implantation (1) (2) (3) (4) . In the United States, 90,000 surgical aortic valve replacements are performed annually, with over three-quarters incorporating bioprosthetic valves (3) . In addition, >80,000 transcatheter aortic valve implantation procedures have been performed since U.S. Food and Drug Administration approval in 2011 (4) . Given the finite lifespan of these valves and the rapid expansion of the population of patients requiring regular surveillance, bioprosthetic valve degeneration will become a major cause of cardiovascular morbidity and health care burden over the coming decades.
The pathophysiology of bioprosthetic valve degeneration is poorly understood. Although calcification appears to contribute to both progressive valve narrowing and leaflet tears (5-7), noninvasive methods for detecting this process have been lacking, and the triggers of valve degeneration and calcification are unknown. Current standard of care relies on serial echocardiography and clinical assessment aimed at detecting the valve dysfunction that occurs only toward the end stages of the degeneration process. Unfortunately, many patients present in extremis with unheralded valve failure due to rapidonset valvular obstruction or regurgitation, with repeat operation a high-risk undertaking. Indeed, emergency repeat aortic valve replacement surgery is associated with a mortality of 22.6% compared with 1.4% for elective repeat surgery (8) . Detection of bioprosthetic valve degeneration is therefore highly desirable, allowing at-risk patients to be identified early, offered close tailored monitoring, and optimized timing of repeat elective intervention, thereby avoiding potentially catastrophic valve failure. 18 F-fluoride positron emission tomography (PET)
has recently been used to image tissue calcification activity in a range of cardiovascular diseases (9) (10) (11) (12) . 18 F-fluoride preferentially binds to areas of developing microcalcification indicative of tissue degeneration (13) that precede the macrocalcification detectable by computed tomography (CT) (14, 15) .
Given that calcification is one of the key pathological processes underlying bioprosthetic valve degeneration, we hypothesized that increased 18 Cartlidge et al. Cartlidge et al.
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ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blockade; CT ¼ computed tomography imaging; eGFR ¼ estimated glomerular filtration rate; LV ¼ left ventricle; MDS ¼ most diseased segment; PET ¼ positron emission tomography; SUV ¼ standardized uptake value; TBR ¼ target-to-background ratio. Table 1) . Target-to-background (TBR) values are annotated on the hybrid PET-CT images in white text. Abbreviations as in Figure 1 .
Contrast-enhanced CT images were not interpretable in 8 patients (11%) due to motion degradation and metallic blooming artefact from the valve struts.
Fourteen subjects (19%) had 1 or more leaflet abnormalities on CT: spotty calcification (n ¼ 5), noncalcific leaflet thickening (n ¼ 5), and pannus (n ¼ 7) (Figure 2) .
PET scans were interpretable in all patients. Table 4 ). Figure 3) . Moreover, baseline 18 F-fluoride uptake correlated strongly with all echocardiographic measures of hemodynamic progression regardless of the method used to quantify 18 F-fluoride uptake ( Table 2) .
On the basis of international guideline criteria Of these patients, 5 had an abnormal baseline CT, whereas all 10 patients had increased 18 Table 6 ).
DISCUSSION
In this multimodality prospective imaging study, we have identified 18 F-fluoride PET-CT as the first noninvasive technique capable of detecting early Cartlidge et al. Our study has several major strengths. This is a comprehensive multimodal imaging study using ultrasound, CT, and PET in patients with 
